Dylan Dupuis
Stock Analyst at Roth MKM
(0.32)
# 3,054
Out of 4,413 analysts
11
Total ratings
11.11%
Success rate
-13.5%
Average return
Main Sectors:
Top Industries:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $0.73 | +864.98% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $3.24 | +239.51% | 2 | Sep 21, 2023 | |
| ASLN ASLAN Pharmaceuticals | Reiterates: Buy | $15 | $0.46 | +3,181.56% | 2 | Aug 14, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $5.08 | +352.76% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $76.43 | -58.13% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $1.56 | +541.03% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $0.73
Upside: +864.98%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $3.24
Upside: +239.51%
ASLAN Pharmaceuticals
Aug 14, 2023
Reiterates: Buy
Price Target: $15
Current: $0.46
Upside: +3,181.56%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $5.08
Upside: +352.76%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $76.43
Upside: -58.13%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $1.56
Upside: +541.03%